| Betterchem |

|
|
| FDA approval activities
for this prescription drug:
Tequin (Gatifloxacin) Tablets, Injection & Dextrose Injection, Bristol-Myers Squibb NDA 21-061/S11, 21-061/S15 & 21-062/S15 12/19/02 1/29/03 4/7/03 Tequin (Gatifloxacin) Tablets & Injection, Bristol-Myers Squibb NDA 21-061/S8/S9/S12 10/31/01 05/08/03 Tequin (Gatifloxacin) Tablets & Injection, Bristol-Myers Squibb NDA 21-061/S7 NDA 21-062/S8 10/12/01 6/19/02 6/19/02 6/19/02 Tequin (Gatifloxacin) Tablets & Injection, Bristol-Myers Squibb NDA 21-062/S9/S10/S12 10/31/01 05/8/03 Tequin (Gatifloxacin) Tablets & Injection, Bristol-Myers Squibb NDA 21-062/S6/S7 08/20/01 05/08/03 Tequin (Gatifloxacin) Tablets & Injection, Bristol-Myers Squibb NDA 21-061/S5/S6 08/20/01 05/08/03 Tequin (Gatifloxacin) Tablets & Injection, Bristol-Myers Squibb NDA 21-404, 21-405, 21-061/S-010, 21-062/S-011, 21-061/S-016 & 21-062/S-017 10/17/02 10/21/02 10/18/02 Tequin (Gatifloxacin) Tablets & IV, 200 and 400mg / IV-10mg/mL vials and 2mg/mL flexible containers, Bristol-Myers Squibb NDA 21-061 NDA 21-062 12/17/99 12/27/99 12/27/99 7/18/01 Tequin (Gatifloxacin) Indications: 1. Acute Bacterial Sinusitis, 2. Community Acquired Pneumonia, 3. Acute Bacterial Exacerbation Chronic Bronchitis, 4. Uncomplicated Urinary Tract Infections, 5. Complicated Urinary Tract Infections, 6. Pyelonephritis, 7. Uncomplicated Gonorrhea Zymar (gatifloxacin) ophthalmic solution, 0.3% Allergan, NDA 21-493 GATIFLOXACIN Injection 10MG /ML(200MG) TEQUIN BRISTOL MYERS SQUIBB 021062 GATIFLOXACIN Injection 10MG /ML(400MG) TEQUIN BRISTOL MYERS SQUIBB 021062 GATIFLOXACIN Injection 2MG /ML(200MG/100ML) TEQUIN BRISTOL MYERS SQUIBB 021062 GATIFLOXACIN Injection 2MG /ML(400MG/200ML) TEQUIN BRISTOL MYERS SQUIBB 021493 GATIFLOXACIN Solution/Drops; Ophthalmic 0.3% ZYMAR ALLERGAN 021061 GATIFLOXACIN Tablet; 200MG TEQUIN BRISTOL MYERS SQUIBB 021061 GATIFLOXACIN Tablet; 400MG TEQUIN BRISTOL MYERS SQUIBB |
|
© 2009 Betterchem.com
|